Core Insights - Shenzhen Jindu Biomedical Technology Co., Ltd. has completed a Pre-A+ round financing, raising tens of millions of RMB, with participation from Nanshan Zhanxin Investment [1][2]. Financing Details - The financing round occurred on November 13, 2025, with Nanshan Zhanxin Investment as the investor [2]. - Previous financing rounds include: - Pre-A round on November 4, 2025, with undisclosed investment from Chuang Dongfang Investment [2]. - Angel+ round on October 14, 2025, raising tens of millions of RMB from HongShan Sequoia China [2]. - Angel round on November 30, 2023, with tens of millions of RMB from Xiantong Capital [2]. - Seed round on February 28, 2023, raising millions of RMB from Shenzhen Jibei Investment Partnership [2]. Company Focus - Jindu Biomedical is focused on developing multimodal medical diagnostic models, emphasizing multi-omics analysis (RNA, DNA, protein, and metabolomics) to enhance diagnostic capabilities [2]. - The first expert model, GeneLLM, is pre-trained on 23 billion sequencing sequences and 3.45 trillion base data, transforming complex biological data into precise medical decision support tools [2]. - The technology leverages research collaboration from top universities, including Oxford University, Peking University, Tsinghua University, and Beihang University, aiming to revolutionize medical diagnostics by integrating multiple omics data for comprehensive disease diagnosis [2].

Core Insights - Chuangdong Investment announced a Pre-A round investment of tens of millions of RMB in Shenzhen Jindu Biomedical Technology Co., Ltd. (referred to as "Jindu Bio") on October 24, with Jiangxi Jin Kong participating in the investment, bringing Jindu Bio's total financing to nearly 100 million RMB to date [1] Company Overview - Jindu Bio possesses the cutting-edge global biological science model GeneLLM and has developed a one-stop biological science research platform called BioFord, along with AI products such as the AI4S Lab digital life science laboratory [1] - The core team, led by founder Dr. Jin Yongcheng, consists entirely of members from the University of Oxford, showcasing a multidisciplinary background in life sciences and artificial intelligence, which highlights the company's composite team characteristics [1] Investment Context - The investment by Chuangdong Investment aligns with its focus on the major sectors of AI and health, indicating a strategic interest in companies that integrate advanced technology with life sciences [1]